1. Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma
   Nozomi Ito et al, 2020, Journal of Surgical Research CrossRef
2. DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine
   Nayeralsadat Fatemi et al, 2022, International Journal of Cancer CrossRef
3. The roles of PD‐1/PD‐L1 and its signalling pathway in gastrointestinal tract cancers
   Chunguo Cui et al, 2019, Clinical and Experimental Pharmacology and Physiology CrossRef
4. Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer
   Weiwei Yu et al, 2018, Medicine CrossRef
5. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
   Ramy R. Saleh et al, 2022, Molecular Diagnosis & Therapy CrossRef
6. Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers
   Negar Khoshghamat et al, 2021, Pathology - Research and Practice CrossRef
7. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types
   Tom van den Ende et al, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
8. MMR markers correlate with clinical outcome in patients with esophageal squamous cell carcinoma
   Takuro Yamauchi et al, 2023, The International Journal of Biological Markers CrossRef
9. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
   Tadayoshi Hashimoto et al, 2019, Gastric Cancer CrossRef
10. Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer
    Yuto Kubo et al, 2023, Annals of Surgical Oncology CrossRef